Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 63.99

+4.7%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: RWReeves who wrote (423)	10/5/1999 5:07:00 AM
From: Doc Bones	Read Replies (3) of 52153

Thanks for the education, RWR. After reading it I found the link below, which is reinforcing what's been said - basically BMT results not good. I do think there are some real political distortions in medicine. When I see congress mandating what procedures are covered, it could be they're protecting the average citizen from the grasping insurance company, but too often it's something else. Doc (honorific, like "Colonel" Sanders <g>) ------------- hslc.org ECRI Patient Reference Guide: High-dose chemotherapy with bone marrow transplant for metastatic breast cancer. Second edition Summary of ECRI's analysis ¸ 1996 ECRI. All rights reserved. This Patient Reference Guide may be reproduced in its entirety for purposes of distribution to patients seeking information about this procedure, provided that it is disseminated to patients and their families at no profit. Please read the Policy Statement. -------------------------------------------------------------------------------- About this Guide -- Contents -- Breast Cancer Stages -------------------------------------------------------------------------------- Summary of ECRI's analysis of all studies on HDC with ABMT/BCT for metastatic breast cancer published through late 1994 Analysis of all studies published through 1994 show that there is an initially higher response rate to HDC with ABMT/BCT than to standard-dose chemotherapy. This means that, at first, the tumor shrinks. However, the response does not last and the cancer progresses. There is evidence that standard-dose chemotherapy offers patients with metastatic breast cancer a longer response time and an increased overall survival time, and more patients survive for one year compared to HDC with ABMT/BCT therapies. There is some evidence of shorter overall survival times after HDC with ABMT/BCT therapies than after standard-dose therapy. Results of a randomized controlled trial published in 1995 (the first such study completed on this procedure for metastatic breast cancer) have not altered these conclusions. The medical research on HDC with ABMT/BCT does not identify any subgroup of patients that is likely to have long-term disease-free survival after receiving the HDC.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next